On the other hand, the use of specific blockade of cellular lactadherin has been reported to have antitumor effects in several types of cancer [50, 75, 76], which suggests that the use of lactadherin-blocking agents in preclinical in vivo tumor growth assays could be an excellent focus for immunotherapy [77]⁠. The gene discussed is MFGE8; the disease is neoplasm.